Standard News

Hide Advertisement
  • Business
  • Culture
  • News
  • Technology
  • Trending
Site logo
ADVERTISEMENT
ADVERTISEMENT

DuPont ordered to pay $5.1 million in trial over Teflon-making chemical

By Reuters 2 min read
Advertisement - Continue reading below
A view of the Dupont logo on a sign at the Dupont Chestnut Run Plaza facility near Wilmington, Delaware

By Jessica Dye

NEW YORK (Reuters) – A U.S. jury on Wednesday ordered DuPont to pay $5.1 million to a man who said he developed testicular cancer from exposure to a toxic chemical used to make Teflon at one of its plants, according to a DuPont spokesman.

Advertisement

It is the second time jurors in Ohio federal court have found against DuPont, which is facing more than 3,400 lawsuits from residents who say they contracted one of six diseases linked to perfluorooctanoic acid, known as PFOA or C-8, which is used to make products such as Teflon non-stick cookware.

Following a five-week trial, jurors deliberated for less than a day before finding DuPont was negligent and awarding $5.1 million in compensatory damages to David Freeman, an Ohio resident who said he developed testicular cancer from his exposure to C-8 in drinking water.

The jury also decided that DuPont had acted with actual malice, a finding that exposes the company to punitive damages, the amount of which will be determined at a proceeding starting Thursday.

A DuPont spokesman declined to comment. While DuPont is the named defendant, a recent spin-off of its performance chemicals segment, Chemours Co, will cover its liability.

A spokeswoman for Chemours, Cynthia Salitsky, said the verdict will be appealed. To the extent DuPont claims indemnification for the verdict, “Chemours retains its defenses to such claims,” she said in a statement.

Lawyers for Freeman did not immediately return a request for comment. The trial was a so-called bellwether, the verdict of which is intended to help the companies and plaintiffs value remaining cases alleging similar facts.

The first trial over C-8 exposure resulted in a $1.6 million verdict and no punitive damages last year.

Chemours shares closed down 22.5 percent at $5.93 in heavy volume. DuPont shares ended down 1.8 percent at $61.85 per share.

(Reporting by Jessica Dye; Additional reporting by Lewis Krauskopf; Editing by Chris Reese)

tagreuters.com2016binary_LYNXNPEC651IF-VIEWIMAGE

Advertisement - Continue reading below

U.S. pump prices rise as Colonial fixes gasoline pipeline leak
News
Reuters 3 min read

U.S. pump prices rise as Colonial fixes gasoline pipeline leak

Fatal shooting of San Diego cop not immediately linked to ambushes
News
Reuters 2 min read

Fatal shooting of San Diego cop not immediately linked to ambushes

Mississippi governor to join suit against Obama transgender policy
News
Reuters 2 min read

Mississippi governor to join suit against Obama transgender policy

Burger King launches Whopperrito in U.S. outlets
News
Reuters 1 min read

Burger King launches Whopperrito in U.S. outlets

Vera Wang, Victoria Beckham debut their spring/summer 2017 looks
Entertainment
Reuters 2 min read

Vera Wang, Victoria Beckham debut their spring/summer 2017 looks

The Conference Board Leading Economic Index® (LEI) for the U.S. Increased in February
Business
Jason Owen 2 min read

The Conference Board Leading Economic Index® (LEI) for the U.S. Increased in February

Obama visits Midway Atoll, a symbol of his climate, Asia legacy
News
Reuters 3 min read

Obama visits Midway Atoll, a symbol of his climate, Asia legacy

Conservatives split over U.S. land transfers to Western states
News
Reuters 4 min read

Conservatives split over U.S. land transfers to Western states

Obama, Clinton scold Trump over proposed Muslim ban
News
Reuters 4 min read

Obama, Clinton scold Trump over proposed Muslim ban

In slap at Trump, some wealthy Republicans campaign for Clinton
News
Reuters 4 min read

In slap at Trump, some wealthy Republicans campaign for Clinton

load more Loading posts...

sidebar

ADVERTISEMENT
ADVERTISEMENT

sidebar-alt

  • About Us
  • Imprint
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • For Advertisers